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In industrialized countries, 30% of HIV-infected pat-
ients and 60—90% of HIV-infected intravenous drug
users (IVDU) are co-infected with the hepatitis C
virus (HCV).1,2 In Western Europe, Portugal has one
of the highest incidence rates of HCV-HIV co-infec-
tion, as well as a large number of intravenous drug
users.3 Factors that have contributed to the spread
of these infections are insufficient knowledge of the
modes of HIV and HCV transmission as well as inef-
fective prevention programmes. In our setting, the
scarcity of prospective studies on the incidence of
HCV-HIV co-infection reinforces the need for cross-
sectional studies.
We conducted a study at a large HIV outpatient
clinic at a teaching hospital in Lisbon in order to
evaluate trends on HCV-HIV co-infection. From 1991
to 2002, a total of 3702 HIV infected patients were
seen. All patients were routinely screened for anti-
bodies to HCV, and 920 (24.9%) were found to be
positive. Most co-infected patients were male
(72.9%), Caucasian (96.0%) and IVDU (91.6%). The
median age was 28 years (range 14—74).Figure 1 Number of HCV-HIV co-infected patients from 199
gender distribution.
1201-9712/$30.00 # 2005 International Society for Infectious Diseas
doi:10.1016/j.ijid.2004.07.011The number of HCV-HIV co-infected patients
increased until 1996 and was then followed by a
steady decrease (see Figure 1). A similar trend was
seen for all HIV-infected patients (data not shown).
The decreasing number of co-infected individuals
found in our study after 1996 probably reflects the
decrease of the number of new infections through
the parenteral route, either because of a reduction
in injection drug use or an increase in safer injecting
practices. In fact, having recognised the impact of
drug users on the HIV epidemic, a national syringe
exchange programme was implemented in 1993. Its
evaluation indicates that the 23 million syringes
exchanged from 1993 to 2001 avoided 7000 HIV
infections.4 Another possibility is that IVDU, showing
a poorer adherence to antiretroviral therapy did not
benefit from its advantages, mainly from its impact
on mortality.
One of the most interesting findings in our study is
a clear increase in the female:male ratio over the
final few years (Figure 1). While during the period
1991—1995 a quarter of the patients were female
(23 to 32%), this number doubled in more recent
years (37 to 57%). As HCV infection can be consid-1—2002. Data show the total number of co-infections and
es. Published by Elsevier Ltd. All rights reserved.
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mission of HIV infection,5 these data could indicate
that there is a relative increase in the number of
female IVDU in the Lisbon area, probably connected
to the sex for drugs trade. If this finding were
extrapolated to the country as a whole, it suggests
that national public health policy should increase its
focus on behavioural interventions to reduce the
frequency of HIVand HCV transmission by IVDU, with
specific emphasis on the female population.
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